HOUSTON, Sept. 10, 2020 /PRNewswire/ -- Soliton, Inc., (NASDAQ:SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced it has entered into a distribution and sales agreement with Aesthetic Solutions, Inc. to distribute its Rapid Acoustic Pulse (RAP) device and advanced design cartridges during the initial U.S. commercial launch, targeted for the first half of 2021.
The team at Aesthetic Solutions, Inc. will strategically focus on and target placement of the RAP device in physician practices that currently treat high volumes of patients for tattoo removal and cellulite reduction, upon FDA clearance. Their team will sell and service the RAP devices until Soliton's direct sales force is fully established for the expected national rollout.
As previously announced under Soliton's COVID-19 Adjusted Commercialization Strategy, the RAP device is planned to incorporate both the tattoo removal indication and the cellulite reduction indication, pending FDA clearance of the cellulite indication.
Join our more than 200K subscribers here to follow the Company:https://soly-investors.com
"We are excited to have set in place a plan for the strategic distribution of our RAP device for our initial commercial launch," commented Christopher Capelli, MD, founder, President and CEO of Soliton. "Aesthetic Solutions has an exceptional reputation in the industry and we believe will generate positive results for Soliton among dermatologists, particularly key opinion leaders with strong relationships with their patients. Our relationship with Aesthetic Solutions represents a key step forward in accomplishing a successful commercial launch and we welcome their team as our sales and distribution partner."
"We are thrilled to partner with Soliton for the sales and distribution of its unique multi-indication aesthetic device," said Tim Howder, President of Aesthetic Solutions, Inc. "With 30 years of experience in aesthetic medical device rentals and distribution, we are excited to apply our unique skill sets in a program of strategic device distribution and service. Our highly trained sales and service staff teams are eager and ready to partner with Soliton to ensure success in the launch of this exciting multi-use device. We are well-equipped to support the company's upcoming launch and we look forward to a successful relationship."
Soliton's RAP technology has not yet been cleared by the FDA for cellulite reduction and is not available for sale in the United States for this indication.